{"success":true,"data":{"pressRelease":{"id":"31791","rtpr_id":"nNFC5vXf3","ticker":"GOSS","exchange":"NASDAQ","all_tickers":["GOSS"],"title":"GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026","author":"Newsfile Corp","published_at":"2026-05-12T13:53:16.940Z","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/GzEZGu0gjv) Encourages Investors Who\nSuffered Losses In Gossamer To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired securities in Gossamer\n(https://api.newsfilecorp.com/redirect/Q2DngSEAkr) between June 16, 2025 and\nFebruary 20, 2026 and would like to discuss your legal rights, call Faruqi &\nFaruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/mjJAOuxnjW)\n\nNew York, New York--(Newsfile Corp. - May 12, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/kXjAEIY7NA), a leading national\nsecurities law firm, is investigating potential claims against Gossamer Bio,\nInc. (\"Gossamer\" or the \"Company\") (NASDAQ: GOSS) and reminds investors of the\nJune 1, 2026 deadline to seek the role of lead plaintiff in a federal\nsecurities class action that has been filed against the Company.\n\n(https://images.newsfilecorp.com/files/6455/296962_d640266d444cdb49_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that the study design for the Company's Phase 3\nPROSERA study, particularly, controlling for the placebo response at the Latin\nAmerican testing sites.\n\nOn February 23, 2026, Gossamer Bio, Inc. revealed adverse topline results from\nits Phase 3 PROSERA study, announcing that the trial failed to meet its\nprimary endpoint of improving six-minute walk distance (\"6MWD\") at Week 24.\nWhile the study reported a placebo-adjusted gain of +13.3 meters, the result\ndid not achieve statistical significance under the prespecified alpha\nthreshold of 0.025 (p=0.0320). The Company attributed the outcome, in part, to\nunexpectedly strong placebo performance among patients enrolled at Latin\nAmerican sites, which it characterized as a heavily treated, lower-risk\npopulation.\n\nFollowing this disclosure, investors and analysts reacted swiftly and\nnegatively. On February 23, 2026, Gossamer's common stock price plummeted from\na closing price of $2.13 per share on February 20, 2026 to $0.42 per share,\nrepresenting a decline of more than 80% in a single trading day.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nGossamer's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Gossamer Bio class action, go to\nwww.faruqilaw.com/GOSS or call Faruqi & Faruqi partner Josh Wilson directly at\n877-247-4292 or 212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/LqynRCGW1B), on X\n(https://api.newsfilecorp.com/redirect/oPQAOTBJmP), or on Facebook\n(https://api.newsfilecorp.com/redirect/OANnEu2OqA).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296962","article_body_html":"","raw_payload":{"data":{"id":"nNFC5vXf3","title":"GOSS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026","author":"Newsfile Corp","ticker":"GOSS","created":"2026-05-12T13:53:16.940Z","tickers":["GOSS"],"exchange":"NASDAQ","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/GzEZGu0gjv) Encourages Investors Who\nSuffered Losses In Gossamer To Contact Him Directly To Discuss Their Options\n\nIf you purchased or acquired securities in Gossamer\n(https://api.newsfilecorp.com/redirect/Q2DngSEAkr) between June 16, 2025 and\nFebruary 20, 2026 and would like to discuss your legal rights, call Faruqi &\nFaruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/mjJAOuxnjW)\n\nNew York, New York--(Newsfile Corp. - May 12, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/kXjAEIY7NA), a leading national\nsecurities law firm, is investigating potential claims against Gossamer Bio,\nInc. (\"Gossamer\" or the \"Company\") (NASDAQ: GOSS) and reminds investors of the\nJune 1, 2026 deadline to seek the role of lead plaintiff in a federal\nsecurities class action that has been filed against the Company.\n\n(https://images.newsfilecorp.com/files/6455/296962_d640266d444cdb49_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that the study design for the Company's Phase 3\nPROSERA study, particularly, controlling for the placebo response at the Latin\nAmerican testing sites.\n\nOn February 23, 2026, Gossamer Bio, Inc. revealed adverse topline results from\nits Phase 3 PROSERA study, announcing that the trial failed to meet its\nprimary endpoint of improving six-minute walk distance (\"6MWD\") at Week 24.\nWhile the study reported a placebo-adjusted gain of +13.3 meters, the result\ndid not achieve statistical significance under the prespecified alpha\nthreshold of 0.025 (p=0.0320). The Company attributed the outcome, in part, to\nunexpectedly strong placebo performance among patients enrolled at Latin\nAmerican sites, which it characterized as a heavily treated, lower-risk\npopulation.\n\nFollowing this disclosure, investors and analysts reacted swiftly and\nnegatively. On February 23, 2026, Gossamer's common stock price plummeted from\na closing price of $2.13 per share on February 20, 2026 to $0.42 per share,\nrepresenting a decline of more than 80% in a single trading day.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nGossamer's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the Gossamer Bio class action, go to\nwww.faruqilaw.com/GOSS or call Faruqi & Faruqi partner Josh Wilson directly at\n877-247-4292 or 212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/LqynRCGW1B), on X\n(https://api.newsfilecorp.com/redirect/oPQAOTBJmP), or on Facebook\n(https://api.newsfilecorp.com/redirect/OANnEu2OqA).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296962"},"type":"article","timestamp":"2026-05-12T13:53:16.980029866Z","server_sent_at_ms":1778593996980},"received_at":"2026-05-12T13:53:17.038Z","source_url":"https://www.newsfilecorp.com/release/296962"},"analysis":{"id":"23104","press_release_id":"31791","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc. and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action.\n\nThe complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements regarding the study design for the Phase 3 PROSERA study, particularly the placebo response at Latin American testing sites.\n\nOn February 23, 2026, Gossamer Bio announced that the Phase 3 PROSERA study failed to meet its primary endpoint, leading to a more than 80% decline in the stock price from $2.13 to $0.42 per share in a single trading day.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"James (Josh) Wilson","role":"Securities Litigation Partner"}],"products":[],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS","relationship":"target"},{"name":"Faruqi & Faruqi, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Faruqi & Faruqi, LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"GOSS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Faruqi & Faruqi, LLP is investigating potential claims against Gossamer Bio, Inc. and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action.\n\nThe complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements regarding the study design for the Phase 3 PROSERA study, particularly the placebo response at Latin American testing sites.\n\nOn February 23, 2026, Gossamer Bio announced that the Phase 3 PROSERA study failed to meet its primary endpoint, leading to a more than 80% decline in the stock price from $2.13 to $0.42 per share in a single trading day.","key_figures":{},"named_entities":{"people":[{"name":"James (Josh) Wilson","role":"Securities Litigation Partner"}],"products":[],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS","relationship":"target"},{"name":"Faruqi & Faruqi, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a76fb3b19e8e8b7b","schema_hash":"sha256:8658c370b800cf3d","created_at":"2026-05-12T13:53:28.099Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":10998,"modelName":"george-droid-qwen-72b"}}